Is Dental Monitoring profitable in 2026?

Dental Monitoring states it achieved operational profitability in 2025, disclosed alongside a $100M funding round announced February 10, 2026 led by Lazard Elaia Capital and ISALT. This is a company statement, not independently audited, so the figure should be treated as unconfirmed.

Could AI replace Dental Monitoring's core product?

Dental Monitoring's product is itself AI-driven, but it holds an FDA De Novo clearance from May 2024 creating a new device category (21 CFR 872.1770) plus a proprietary dataset it describes as two billion images, both hard for a new AI entrant to replicate quickly.

Who is Dental Monitoring's biggest competitor?

Align Technology, maker of Invisalign, is the biggest threat. It shipped its own AI monitoring tool, Invisalign Virtual Care AI, and won two Federal Circuit rulings in July 2026 invalidating core Dental Monitoring machine-learning patents.

Who owns Dental Monitoring?

Dental Monitoring is privately held and VC/PE-backed, headquartered in Paris under CEO Philippe Salah. Major investors include Mérieux Equity Partners and Vitruvian Partners from its 2021 unicorn round, plus Lazard Elaia Capital and ISALT from a $100M raise announced February 10, 2026.

Is Dental Monitoring doing layoffs?

No layoffs are reported. Headcount tracking shows roughly 547 employees as of December 2025, essentially flat versus 544 in 2024, consistent with the company's stated focus on reaching profitability rather than expanding headcount.

What is Dental Monitoring's valuation?

Dental Monitoring became a unicorn in October 2021 after a $150M growth round led by Mérieux Equity Partners ($90M) and Vitruvian Partners ($60M), pushing its valuation over $1 billion, making it one of France's HealthTech unicorns.

France · France

Dental Monitoring

AI app that tracks orthodontic treatment progress between dentist visits.

Protection under test

Assessed 29 July 2026 · Evidence as of 29 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 29 July 2026 · Checkable from ~July 27, 2026 · Every call on the record Checkpoint: Federal Circuit certified-list deadline for DM's patent appeal, Case 26-1945

The call

DM holds regulatory clearances and cross-brand reach while Align ships its own AI tool and chips away at DM's patents, with no clear winner yet.

Dental Monitoring builds software that uses phone cameras and AI to let orthodontists check patients' braces without in-person visits. It is hard to copy because it has FDA approval, EU medical device clearance, and a huge library of 2 billion images that trained its AI system. But Align Technology, which makes Invisalign (the most popular clear braces brand), just launched its own competing tool and won two major patent court battles in July 2026 that knocked out Dental Monitoring's core technology patents. The biggest question is whether Align will use its massive Invisalign patient base to slowly squeeze out Dental Monitoring, or whether Dental Monitoring's partnerships with other brace brands like Ormco and Straumann will keep it alive as an independent company.

Why

AI pressure: Align Technology's Invisalign Virtual Care AI. Align built its own AI monitoring tool for Invisalign patients, competing directly inside DM's biggest addressable market. Could AI do the core job? Unlikely.

Bigger players: Align Technology / Invisalign. Align can bundle monitoring free with Invisalign and won two 2026 patent rulings against DM's machine-learning claims. Could a giant copy it? Probably.

What protects it. FDA De Novo and EU-MDR clearances plus a 2B-image dataset and neutral fit across Ormco, Straumann and other brands Align can't serve.

What would change this call

Federal Circuit ruling in Case 26-1945 (certified list due ~July 27, 2026). Shows whether Dental Monitoring's core ML patents survive Align's challenge.
Align licenses or rebrands Invisalign Virtual Care AI as a standalone, brand-neutral product. Would show Align competing directly for Ormco/Straumann-aligner patients, not just its own.
Ormco/Spark or Straumann/ClearCorrect ends or expands its partnership with Dental Monitoring. Tests whether DM's aligner-neutral positioning is holding against Align's pressure.

Key numbers

FDA De Novo clearance granted, new device category (2024-05-20)
$100M raised, led by Lazard Elaia Capital (2026-02-10)
Over 2 million patients monitored (2026-04-02)

Named risks

Core ML patents invalidated by Federal Circuit in July 2026, weakening IP moat against Align. Severity: high
No independently audited revenue disclosure; third-party estimates range from $32.7M to $91M. Severity: medium
Align's dominant Invisalign base and own AI tool could starve DM of addressable market. Severity: high
Pending Federal Circuit appeal Case 26-1945 with certified-list deadline around July 27, 2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Align Technology (Invisalign)	losing to	Federal Circuit invalidated two DM ML patents July 7 and July 21, 2026 in Align's favor
Grin	contesting	Cited as closest direct rival with its own Scope hardware, per March 2026 competitive analysis
Overjet and Pearl AI	contesting	Adjacent diagnostic-AI rivals accumulating FDA clearances through 2024, partial substitutes

Questions people ask

Is Dental Monitoring profitable in 2026?: Dental Monitoring states it achieved operational profitability in 2025, disclosed alongside a $100M funding round announced February 10, 2026 led by Lazard Elaia Capital and ISALT. This is a company statement, not independently audited, so the figure should be treated as unconfirmed.
Could AI replace Dental Monitoring's core product?: Dental Monitoring's product is itself AI-driven, but it holds an FDA De Novo clearance from May 2024 creating a new device category (21 CFR 872.1770) plus a proprietary dataset it describes as two billion images, both hard for a new AI entrant to replicate quickly.
Who is Dental Monitoring's biggest competitor?: Align Technology, maker of Invisalign, is the biggest threat. It shipped its own AI monitoring tool, Invisalign Virtual Care AI, and won two Federal Circuit rulings in July 2026 invalidating core Dental Monitoring machine-learning patents.
Who owns Dental Monitoring?: Dental Monitoring is privately held and VC/PE-backed, headquartered in Paris under CEO Philippe Salah. Major investors include Mérieux Equity Partners and Vitruvian Partners from its 2021 unicorn round, plus Lazard Elaia Capital and ISALT from a $100M raise announced February 10, 2026.
Is Dental Monitoring doing layoffs?: No layoffs are reported. Headcount tracking shows roughly 547 employees as of December 2025, essentially flat versus 544 in 2024, consistent with the company's stated focus on reaching profitability rather than expanding headcount.
What is Dental Monitoring's valuation?: Dental Monitoring became a unicorn in October 2021 after a $150M growth round led by Mérieux Equity Partners ($90M) and Vitruvian Partners ($60M), pushing its valuation over $1 billion, making it one of France's HealthTech unicorns.

Timeline

2026-07-21Federal Circuit affirmed PTAB ruling that DM patent claims were unpatentable as obvious
2026-07-07Federal Circuit affirmed invalidation of two DM machine-learning patents under Section 101
2026-06-15New Federal Circuit appeal (Case 26-1945) filed by Dental Monitoring
2026-02-10Dental Monitoring secures $100M led by Lazard Elaia Capital; claims 2025 profitability
2025-10Integration launched with Straumann's ClearCorrect aligner platform
2025-04Partnership announced with Ormco/Spark Clear Aligners
2024-11-20Major software update adds FDA-validated AI clinical indications and EU-MDR features
2024-05-20Dental Monitoring receives FDA De Novo clearance, creating new device category
2021-10-21Dental Monitoring becomes unicorn after $150M round, valuation over $1 billion

Revision history

29 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Swile Inetum Fnac Darty